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Abstract 
Background: Helicobacter pylori is a pathogenic bacterium that causes various gastrointestinal diseases. The most 
common gastric malignancies associated with H. pylori are gastric cancer and lymphoma of mucosa associated 
lymphoid tissue (MALT). Helicobacter pylori virulence genes, namely cagA and vacA, are known to be associated with 
malignancy development. Conventionally, cagA and vacA were classified by looking at partial sequences of the genes. 
However, such genotyping has hardly proven useful predicting different risks for gastric cancer or MALT lymphoma. In 
search of new loci that distinguish these diseases, we investigated the full sequences of cagA and vacA.
Results: We compared cagA and vacA sequences of 18 and 12 H. pylori strains obtained, respectively, from patients 
with gastric cancer and MALT lymphoma in Oita, Japan. Conventional genotyping of cagA and vacA showed no 
significant difference between the two diseases. We further investigated the full protein sequences of CagA and VacA 
to identify loci where allele frequency was significantly different between the diseases. We found four such loci on 
CagA, and three such loci on VacA. We also inspected the corresponding loci on the genes of 22 gastritis strains that 
potentially lead to gastric cancer or MALT lymphoma in the long run. Significant differences were observed at one 
CagA locus between gastritis and MALT lymphoma strains, and at one VacA locus between gastritis and gastric cancer 
strains.
Conclusions: We found novel candidate loci in H. pylori virulence genes in association with two different types of 
gastric malignancies that could not be differentiated by conventional genotyping. Biological connotations of the 
amino acid polymorphisms merit further study.
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Background
More than half of the world’s population is infected with 
Helicobacter pylori, a gram-negative spiral bacterium 
whose ecological niche is the human stomach. The infec-
tion is associated with severe gastritis-associated dis-
eases, including peptic ulcer disease, gastric cancer (GC), 
and lymphoma of mucosa associated lymphoid tissue 
(MALT lymphoma) [1]. Most H. pylori-infected individu-
als develop histological gastritis, and about 10% of those 
infected develop severe diseases [2].
Epidemiological studies suggested that H. pylori infec-
tion plays an oncogenic role in both GC and MALT lym-
phoma [3–5]. Over their entire lifetimes, ~1 to 2% of H. 
pylori infected individuals develop GC, and less than 
0.1% of them develop MALT lymphoma [6, 7]. The mech-
anisms for H. pylori involvement in these two kinds of 
malignant diseases remain unknown.
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Helicobacter pylori is a highly heterogeneous species, 
and its virulence varies geographically [8]. The bacterial 
factors cytotoxin-associated gene A (CagA) and vacuolat-
ing cytotoxin A (VacA) are the most extensively studied 
H. pylori virulence factors. The major H. pylori virulence 
factor CagA is translocated into gastric cells via type IV 
secretion system and plays an important role in gastric 
carcinogenesis [9–11]. Injection of CagA requires a host 
cell receptor that was identified as integrin beta 1 [12, 
13]. Recently there are several evidences that CagA also 
injected into B-cells in gastric MALT lymphoma [14, 15]. 
There are two types of clinical isolates: CagA-producing 
(cagA-positive) and CagA non-producing (cagA-neg-
ative) strains. The CagA protein contains a C-terminal 
region containing Glu-Pro-Ile-Tyr-Ala (EPIYA) tyrosine-
phosphorylation motifs. The sequences are annotated 
according to segments (20–50 amino acids) flanking the 
EPIYA motifs (i.e., segments EPIYA-A, -B, -C, or -D) 
[16–18]. cagA containing EPIYA-D segments is typi-
cally observed in strains isolated from East Asia, and is 
denoted as East-Asian-type cagA; whereas cagA contain-
ing EPIYA-C segments is observed globally in non-East 
Asia strains, including those from Europe, South Asia, 
Africa, Australia, and the American continents, and is 
denoted Western-type cagA [19]. East-Asian-type cagA 
exhibits a stronger binding affinity for src homology-2 
domain-containing phosphatase 2 (SHP2), and a greater 
ability to induce morphological changes in epithelial 
cells, than Western-type cagA [8, 16]. Our in vivo epide-
miological studies also revealed a higher prevalence of 
East-Asian-type cagA strains in patients with GC than 
in patients with gastritis, and confirmed that East-Asian-
type cagA is a significant risk factor for GC in Okinawa 
(Japan) and Thailand [20, 21]. Such different types of H. 
pylori virulence factor, at least in part, affect the geo-
graphic differences in incidence of gastric malignancies.
VacA is another extensively studied H. pylori virulence 
factor. Although nearly all strains possess the vacA gene. 
VacA protein posesses the capacity to induce cell vacu-
olization was found to differ significantly from strain to 
strain [22]. Four high sequence diversity regions of vacA 
have been found to closely associate with H. pylori vacu-
olating activity, including signal (s)-, intermediate (i)-, 
middle (m)-, and deletion (d)-regions. s, i, m, d regions 
are classified either type 1 or 2, respectively, and vacA 
s1m1 type is related with the higher risk of gastric malig-
nancies [23, 24].
In Japan, almost all strains have ABD-type cagA and 
s1m1-type vacA, which are the most virulent genotypes, 
although clinical outcomes of the infection vary [25–27]. 
Conventional genotyping based on the partial sequences 
of the genes are not enough to predict different risks for 
gastric cancer or MALT lymphoma. Although the genetic 
diversity of these factors affects the pathogenesis of asso-
ciated malignancies, few previous studies have focused 
on the entire sequences of cagA and vacA [28]. We there-
fore investigated the full protein sequences of CagA and 
VacA to identify amino acid loci where the allele fre-
quency is significantly different between H. pylori strains 
isolated from patients with GC and MALT lymphoma. 
The differing amino acid residues were further compared 
with their corresponding amino acids in H. pylori strains 
isolated from patients with gastritis, who principally were 
individuals who may develop either GC or MALT lym-
phoma in the future.
Methods
Patients and H. pylori
Helicobacter pylori strains were isolated from the gas-
tric mucosa of Japanese patients infected with H. pylori 
who underwent endoscopy at Oita University Faculty of 
Medicine Hospital (Yufu, Japan) and its affiliated hospi-
tals (Oita, Japan) between February 1997 and April 2014. 
Included presentations were gastritis only (i.e., histologi-
cal gastritis without peptic ulcers nor any malignancy), 
GC, and MALT lymphoma. We analyzed 18, 12, and 22 
strains obtained from patients with GC, MALT, and gas-
tritis, respectively. For patients with GC, MALT, and gas-
tritis, respectively, the average age and the (male/female 
ratio) were 64.3 a (9/9), 64.4 a (8/4), and 57.9 a (9/13). 
Gastric biopsy specimens were taken from the antrum 
(pyloric gland area) and the corpus (fundic gland area). 
GC were identified by endoscopy; GC and MALT lym-
phoma were further confirmed by histopathology [29]. 
Written informed consent was obtained from all partici-
pants, and the protocol was approved by the Ethics Com-
mittees of Oita University Faculty of Medicine (Yufu, 
Japan).
Isolation of H. pylori
Antral biopsy specimens were obtained for the isola-
tion of H. pylori using standard culture methods, as 
previously described [25]. Helicobacter pylori DNA was 
extracted from confluent plate cultures expanded from a 
single colony using DNeasy Blood & Tissue kit (QIAGEN 
Inc., Valencia, CA, USA).
Gene sequencing and data acquisition
Genome sequence data of H. pylori strains were obtained 
using paired-end reads (2  ×  150 or 2  ×  300  bp) on 
HiSeq  2000 and MiSeq sequencers (Illumina, Inc., San 
Diego, CA, USA). Sample multiplexing was provided by 
using an Indexed DNA library, and manipulated using 
the Nextera XT Index Kit and the Nextera XT DNA 
Library Preparation Kit (Illumina, Inc., San Diego, CA, 
USA), following the manufacturer’s instructions. We 
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performed de-novo assembly of the short read data using 
the CLC Genomics Workbench v. 7.0.4 commercial soft-
ware (CLC QIAGEN), with automated word size and 
bubble size, and a minimum contig size 200  bp. ORFs 
were predicted by the same software, which identified 
CagA and VacA using the genes of Japanese strain F32 
(Accession Number NC_017366). We took top hit genes 
whose % identity and length coverage were at least 85 
and 80%, respectively. In case cagA and vacA genes were 
not detected by next-generation sequencing, we used 
PCR and the Sanger method. Primers for PCR amplifica-
tion and direct sequencing of the entire coding regions 
of cagA and vacA are shown in Table 1. The regions con-
taining full-length cagA and vacA were amplified by PCR, 
and sequenced as previously described. We attached a list 
of accession numbers of the cagA and vacA sequences as 
Additional file 1.
Comparison of amino acid frequency
We first investigated the genotypes of cagA and vacA 
by conventional motif analysis. East-Asian ABD-type 
cagA sequences (13 GC strains and 8 MALT strains), 
and s1m1-type vacA sequences (15 GC strains and 10 
MALT strains) were deposited to GeneBank (Accession 
No. LC185348-LC185429) and used for further analysis. 
We aligned protein sequences of the genes using MAFFT 
v6.717b. We next investigated difference of amino acid 
allele frequency between GC and MALT strains for each 
locus using an original Perl script (detailed information 
available upon request). The significance of each amino 
acid difference was tested using Fisher’s exact test, as 
implemented by the R statistics software.
MLST analysis
To investigate whether the observed differences in amino 
acid frequency could be explained by population struc-
ture, we used multi locus sequence typing (MLST) meth-
ods to construct a phylogenetic tree. Seven housekeeping 
genes of MLST (atpA, efp, mutY, ppa, trpC, ureI, and 
yphC) were obtained in the same manner as vacA and 
cagA. Specific portions of these genes were concatenated 
into sequences of 3406  bp each. We also downloaded 
from the PubMLST database 1439 reference strains with 
bacterial population information determined by STRUC-
TURE analysis in previous studies (http://pubmlst.
org/helicobacter/). We next integrated the reference 
sequences with our sequences, and constructed a phylo-
genetic tree using MEGA v. 6.0.
Results
Conventional genotyping of cagA and vacA
We first analyzed the genotypes of these genes using 
DNA sequences obtained by next generation sequenc-
ing (NGS) or Sanger methods. The cagA genotype was 
classified by its combination of C-terminal EPIYA region 
segments denoted as A, B, C, and D. cagA with ABC seg-
ments was classified as Western type; cagA with ABD 
segments was classified as East-Asian type (Table 2). We 
analyzed cagA sequences of 14 GC and 11 MALT strains 
obtained by either NGS or the Sanger method. Most GC 
strains (13/14 strains; 92.9%) possessed East-Asian type 
ABD cagA, except for one cagA-negative strain. While 
most MALT lymphoma strains (8/11; 72.7%) also pos-
sessed East-Asian type ABD cagA, we also identified 1 
Western type ABCC cagA, 1 AB type, and 1 atypical East-
Asian ABABD type. Recent data revealed a strong non-
random distribution of the B-motifs (including EPIYA 
and EPIYT) in CagAs. The EPIYT B-tyrosine phospho-
rylation motifs (TPMs) were significantly less associated 
with GC than the EPIYA B-TPMs [30]. In this study, most 
strains possessed EPIYA B-TPMs, except for three strains 
with ESIYA or ESIYT B-TPMs (one strain from GC had 
ESIYA B-TPM, and one strain from gastritis and one 
strain from MALT lymphoma had ESIYT B-TPM).
Table 1 Primers used for DNA sequencing of H. pylori cagA 
and vacA in this study
Gene Primer Sequence (5′–3′) References











hp552−R1 GCCTGGATCGCTCAAACTTGGCATGC In this study
cagA−R2 GGGTGTTGATTTTAGACGGATC In this study
cagA−F9 TCGTTCAAGTTTTCCACCAAGTTGA In this study
cagA−F11 CAATCAAGAGGCTAGTAAGGAAG In this study
cagA−F6 CTCTCAAAGATTATGGGAAAAAA In this study
cagA−F10 ACAATAACGTTCTATCTTCTGTGCT In this study







GAATTTCAATGAAGAAGACTTGTT In this study







CTTATTGTTACTGGATGAGCCTA In this study
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Sequences of vacA were categorized by their combina-
tions of s, m, i, and d regions (Table 3). We analyzed vacA 
sequences of 17 GC and 12 MALT strains obtained by 
either NGS or the Sanger method. Each region was clas-
sified into two types, such as s1 and s2; each type 1 sig-
nified virulence, and each type 2 signified non-virulence. 
Most GC strains (15/17 strains: 88.2%) were s1m1i1d1-
type, while most MALT lymphoma strains (10/12: 83.3%) 
were also s1m1i1d1-type. Somewhat interestingly, d2 
genotypes were observed only in MALT lymphoma 
strains (2/12 strains). However, as expected, most strains 
isolated from Japanese patients with GC and MALT lym-
phoma were East-Asian-type cagA and s1m1i1d1 vacA 
genotypes; we could not find the genotypes specific for 
those diseases in Japan. We therefore investigated entire 
sequences of cagA and vacA genes to identify disease-
specific loci at which significant differences in amino acid 
frequency were observed between GC and MALT lym-
phoma strains. Since different genotypes possessed dif-
ferent motifs and repeats, we focused on cagA with ABD 
segments and vacA of s1m1i1d1 type, which possessed 
stronger virulence than other genotypes, and predomi-
nate among East Asian H. pylori.
Significant difference of amino acid frequency 
between samples of GC and MALT lymphoma
We detected disease-specific differences at four cagA loci 
in strain 26,695 (sites 314, 594, 684, and 1077) (left half of 
columns in Table 4; Fig. 1). At cagA site 314, asparagine 
(N) was dominant in the GC group, while serine (S) was 
the majority state in the MALT group. At site 594 of cagA, 
serine (S) was dominant in the GC group, while leucine 
(L) was the majority state in the MALT group. At site 684 
of cagA, isoleucine (I) was dominant in the GC group, 
whereas the MALT group exhibited four amino acid 
variants, with valine (V) the most common among them. 
Among six kinds of amino acid substitution at cagA site 
1077, serine (S) was dominant in the GC group; residues 
other than asparagine (N) exhibited similar frequencies 
in the MALT group. All four of these CagA loci differed 
significantly (P < 0.05, Fisher’s exact test) between the 13 
GC samples and the 8 MALT lymphoma samples.
We detected significant differences in three vacA loci at 
sites 672, 921, and 1037 in strain 26,695 (left half of Table 5; 
Fig. 2). At vacA site 672, isoleucine (I) was dominant in the 
GC group, while valine (V) was dominant in the MALT 
group. At vacA site 921, asparagine (N) predominated in 
both the GC and the MALT groups; however, some aspar-
tic acid (D) substitutions occurred in the MALT group. 
At position 1037 of vacA, serine (S) predominated in both 
groups, but the frequencies of asparagine (N) and glycine 
(G) differed. All three of these VacA loci differed signifi-
cantly (P  <  0.05, Fisher’s exact test) between the 15 GC 
samples and the 9 MALT lymphoma strains.
Absence of population structure confirmed by MLST 
phylogeny
If the samples were taken from different populations and 
disease prevalence was different between the popula-
tions, amino acid frequency could differ not because of 
the diseases but because of the populations. To test for 
structure within the studied strain population, we con-
structed phylogenetic trees based on MLST sequences. 
MLST uses seven housekeeping genes; therefore, a phy-
logenetic tree based on MLST reflects lineage differences 
that are independent of virulence. If adenocarcinoma 
strains and lymphoma strains were divided into two clus-
ters in the MLST tree, amino acid differences may be 
irrelevant to disease type.
In the MLST phylogenetic tree with global strains, both 
GC and MALT lymphoma groups were located around 
East Asian strains (Additional file 2: Figure S1). The phy-
logenetic tree of only Japanese strains exhibited a radial 
branching shape, and GC and MALT lymphoma strains 
scattered randomly (Additional file  3: Figure S2). These 
trees imply an absence of population structure among the 
GC and MALT lymphoma samples.
Significant differences in loci between GC or MALT 
lymphoma and gastritis strains
The significant disease-specific cagA and vacA varia-
tions were not due to sample population differences. We 
Table 2 Strain used for cagA analysis










Entire cagA studied ABD 13 8
Table 3 Strain used for vacA analysis








Entire vacA studied s1m1i1d1 15 10
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therefore compared loci in gastritis samples with their 
counterparts in GC and MALT lymphoma samples; 
these samples were obtained at the same hospitals in 
Japan. Both of the malignant diseases were presumed to 
be derived from gastritis, so we examined the same cagA 
and vacA loci for 22 gastritis strains, and compared these 
observations with corresponding amino acid frequencies 
for GC and MALT lymphoma samples.
Four cagA loci in gastritis samples (positions 314, 
594, 684, and 1077) were checked (right half of Table 4; 
Fig. 1). We analyzed cagA sequences of 18 gastritis strains 
obtained by either NGS or the Sanger method. Two cagA 
Table 4 Difference of amino acid frequency at loci: comparison of each disease in genotypes of cagA ABD type
Position Amino acid 
residue
Gastric cancer (GC) 
(n = 13)
MALT (n = 8) P value Gastritis (G) 
(n = 18)
P value
26,695 F32 GC vs MALT G vs GC G vs MALT
314G 310N G 1 0 0.017 0 0.71 0.0078 (P < 0.01)
N 11 2 16
S 1 4 1
Sequence gap 0 2 1
594L 590S L 3 6 0.032 5 1 0.081
S 10 2 12
Sequence gap 0 0 1
684I 680V I 11 2 0.011 9 0.33 0.63
N 0 1 2
T 0 1 1
V 2 4 5
Sequence gap 0 0 1
1077N 1064S D 1 1 0.029 3 0.58 0.46
H 1 2 2
N 4 0 4
S 7 2 5
T 0 3 2
G 0 0 2
AA site in 26695 307 314 321 587 594 601 677 684 691 1070 1077 1084
26695 V L M G S H N G I E P E K V S K E L A G K A L N F N K A V A Y T Q N L K G I K R E L S D K R I N S N I Q N G A I N E K A
AA site in F32 303 310 317 583 590 597 673 680 687 1057 1064 1071
F32 M . . . . . S N . . . . . . . . . M V . . V S . . . . . . . F D P . . . . V R S . . . . . . . . . . V . S . T . . . . .
Oita strain number and diesase
00-255_GC M . . . . . S N . . . . . . . . . M V . . V S . . . . . . . F D P S . . . . R S . . . . . . . . . . V . S . . . . . . .
00-37_GC . . . . G . S N . . . . . . . . . . L . . V S . . . . . . . F D P S . . . . R S . . . . . . . . . . V . S . . . . . . .
04-140_GC . . . . G . S N . . . . . . . . . . V R . V S . . . . . . . F D P . . . . . R S . . . . . . . . . . V K . . I . . . . .
00-504_GC . . . . . . S N . . . . . . . . . . V . . V S . . . . . . . F D P . . . . . R S . . . . . . . . . . V . . . T L . . . .
10-354_GC . . . . G . S N . . . . . . . . . M V R . V S . . . . . . . F D P . . . . . R S . . . . . . . . . . V H . . T . . . . .
01-273_GC . . . . . . S N . . . . . . . . . M V . . V . . . . . . . . F D P . . . . . R S . . . . . . . . . . V . S . . . . . . .
07-223_GC . . . . G . S N . . . . . . . . . M V . . V . . . . N . . . F D P . . . . . R S . . . . . . . . . . V . S . T . . . . .
01-314_GC . . . . G . S N . . . . . . . . . M V R . V S . . . . . . . F D P . . . . V R S . . . . . . . . . . V . S . . . . . . .
05-134_GC . . . . . . S S . . . . . . . . . . V V G V S . L . . . . . F D P . . . . V R S . . . . . . . . . . V . S . T . . . . .
10-358_GC . . . . . . . . . . . . . . . . . M V . . V S . . . . . . . F D P . . . . . R S . . . . . . . . . . V K . . I . . . . .
10-447_GC . . . . G . S N . . . . . . . . . M V . . V . . . . . . . . F D P . . . . . R S . . . . . . . . . . V . D . T . . . . .
10-453_GC . . . . G . S N . . . . . . . . . M V . . V S . . . . . . . F D P S . . . . R S . . . . . . . . . . V . S . T . . . . .
10-77_GC . . . . . . S N . . . . . . . . G . V . . V S . . . . . . . F D P . . . . . R S . . . . . . . . . . V . H . T . . . . .
09-294_MALT . . . . . . S S . . . . . . . . . M V . . V . . . . . . . . F D P S . . . . R S . . . . . . . . . . V . D . T . . . . .
10-456_MALT - - - - - - - - - - - - - - - . . M V . . V S . . . . . . . F D P . . . . V R S . . . . . . . . . . V . H . . . . . . .
01-543_MALT - - - - - - - - - - - - - - - . . M V . . V . . . . . . . . F D P . . . . T R S . . . . . . . . . . V . T . T . . . . .
13-330_MALT . . . . . . S N . . . . . . . . . M V R . V . . . . . . . . F D P . . . . V R S . . . . . . . . . . V . T . T . . . . .
14-200_MALT M . . . . . S N . . . . . . . . . M V . . V . . . . . . . . F D P . . . . V R S . . . . . . . . . . V . H . T . . . . .
10-442_MALT . . . . G . S S . . . . . . . . . . . . . V . . . . . . . . F D P . . . . N R I . . . . . . . . . . V . S . T . . . . .
99-597_MALT . . . . . . S S . . . . . . . . . M V . . V . . . . . . . . F D P . . . . . R S . . . . . . . . . . V . T . T . . . . .
04-303_MALT . . . . G . S S . . . . . . . . . M V . . V S . . . . . . . F D P . . . D V R S . . . . . . . . . . V . S . . . . . . .
03-132_G . . . . . . S N . . . . . . . . . . V V . V S . . . . . . . F D P . . . . . R S . . . . . . . . . . V . H . T . . . . .
02-425_G . . . . G . S N . . . . . . . . . M V . . V S . . . . . . . F D P . . . . V R S . . . . . . . . . . . H . . T . . . . .
01-540_G . . . . . . S N . . . . . . . . . M V . . V . . . . . . . . F D L . . . . V R S . . . . . . . . . . V . D . T . . . . .
01-383_G . . . . . . S N . . . . . . . . . M V . . V S . . . . . . . F D P . . . . . R S . . . . . . . . . . V . S . T . . . . .
02-331_G . . . . . . . N . . . . . . . . . M V . . V . . . . . . . . F D P . . . . N R S . . . . . . . . . . V . D . T . . . . .
02-29_G . . . . G . S N . . . . . . . . . M V . . V . . . . . . . . F D P . . . . V R S . . . . . . . . . . V . S . T . . . . .
01-487_G . . . . . . S N . . . . . . . . . M V . . V S . . . . . . . F D P S . . . . R S . . . . . . . . . . V . T . T . . . . .
01-381_G . . . . G . S N . . . . . . . . . M V R . V S . . . . . . . F D S . . . . . R S . . . . . . . . . . V H . . T . . . . .
01-97_G . . . . . . S N . . . . . . . . . M V . . V S . . . . . . . F D S . . . . . R S . . . . . . . . . . V H . . . . . . . .
00-466_G . . . . . . S N . . . . . . . . . M V . . V S . . . . . . . F D S . . . . V R S . . . . . . . . . . V . H . . . . . . .
01-375_G . . . . . . S N . . . . . . . . . M V . . V . . . . . . . . F D P . . . . T R S . . . . . . . . . . V . T . T . . . . .
01-69_G . . . . G . S S . . . . . . . . . M V . . V S . . . . . . . F D P . . . . V R S . . . . . . . . . . V . G . T . . . . .
01-633_G M . . . . . S N . . . . . . . . . . L . . V S . . . . . . . F D P . . . . . R S . . . . . . . . . . V . S . T . . . . .
03-8_G . . . . . . S N . . . . . . . . . . L . . V S . . . . . . . F D P . . . . . R S . . . . . . . . . . V . S . . . . . . .
01-617_G . . . . . . . N . . . . . . . . . M V R . V S . . . . . . . F D L . . . . . R S . . . . . . . . . . V K D . T . . . . .
01-643_G - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - . . . . . V . G . . . . . . .
01-23_G M . . . . . S N . . . . . . . . . . . . . V S . . . . . . . F D P . . . . N R I . . . . . . . . . . V . . . T L . . . .
01-524_G . . . . . . S N . . . . . . . . . M V . . V . . . . . . . . F D P . . . . . R S . . . . . . . . . . V . S . . . . . . .
Domain II
17 192
Disordered C-terminal tail 
CagA structure
Domain IIIDomain II
1β β α α
Fig. 1 CagA amino acid comparison between MALT lymphoma, gastric cancer, and gastritis strains. CagA amino acid comparison of strains 26,695, 
F32, and clinical isolates obtained in Oita, Japan are presented. Four significantly different loci are shown in white letters with black background. CagA 
structure was referred to [31]. GC gastric cancer, G gastritis
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positions (684 and 1077) in the gastritis samples were 
not significantly different from their counterparts in GC 
or MALT lymphoma samples. Amino acid frequency of 
gastritis samples seems to be intermediate between GC 
and MALT lymphoma samples. However, cagA posi-
tion 314 in gastritis samples was significantly different 
(P  =  0.008, Fisher’s exact test) from its counterpart in 
MALT lymphoma samples, but very similar to GC sam-
ples (P =  0.71). Also, cagA 594 in gastritis samples had 
the same tendency of near significant difference from 
MALT lymphoma samples (P = 0.081), but was indistin-
guishable from GC samples (P = 1.0). From this analysis, 
H. pylori cagA in patients with MALT lymphoma had the 
residues 314S and 594L, whereas the patients with gastri-
tis and GC patient often had the residues 314N and 594S.
We next checked three vacA loci (positions 672, 921, 
and 1037) in gastritis samples (right half of Table  5; 
Fig. 2). Since we could not obtain vacA sequences from 
four gastritis strains (these strains lacked cagA), 18 
sequences were analyzed. Two vacA positions (672 and 
1037) of gastritis samples were not significantly differ-
ent from their GC or MALT lymphoma counterparts. 
However, one vacA position (921) differed significantly 
between gastritis samples and GC samples (P  =  0.004, 
Fisher’s exact test). This position did not differ signifi-
cantly between gastritis samples and MALT lymphoma 
samples (P = 0.69). The H. pylori vacA from patients with 
gastritis and MALT lymphoma assumed either a D or 
N state at position 921; the homologous position in GC 
patient H. pylori was a conserved N.
Discussion
We found disease-specific amino acid variations at four 
loci in ABD-type CagA (positions 314, 594, 684, and 1077 
in strain 26,695), and at three loci in s1m1-type VacA 
(positions 672, 921, and 1037), some of which deviated 
significantly between GC strains and MALT lymphoma 
strains. There were no differences in the amino acid fre-
quency in all four CagA loci between GC and gastritis. 
Since gastritis cases in this study comprised atrophic gas-
tritis—the precancerous phase—these results were not so 
surprising. However, CagA position 314 was significantly 
different between MALT lymphoma and gastritis strains. 
Most GC and gastritis strains contained asparagine (N) 
at position 314, but MALT lymphoma strains contained 
mainly serine (S) (4/6 sequenced strains). This difference 
suggested that N to S substitution at site 314 might be 
involved with the development of MALT lymphoma.
Recent studies have suggested that CagA would play a 
pivotal role in gastric MALT lymphoma pathogenesis [9, 
14, 15]. CagA was indicated to translocate into human 
B-lymphocytes, hindering their apoptosis. This CagA 
translocation presumably leads to continuous B-lym-
phoid cell proliferation. Genetic variations of CagA in 
the development of MALT lymphoma are still unknown, 
although diversity has been indicated to affect the extent 
to which CagA causes inflammation to gastric epithelial 
cells. Here, we report disease-specific CagA sites that 
may discriminate between GC and MALT lymphoma.
From the view point of the CagA tertiary structure, 
deduced from the protein structure of the 26,695 refer-
ence strain was reported [31], and residue 314 is located 
in the middle region of CagA, in Domain II of β-sheet 
1, continuing from N-terminal Domain I; position 594 
is located in α-helix 17 of Domain II (Figs.  1, 3). Both 
loci are close to the basic amino acid cluster at α-helix 
18 in Domain II where mediates CagA membrane asso-
ciation, so near plasma membrane of host cells. We also 
used structural homology modeling of MALT lymphoma 
strain (09-294) CagA (Fig.  4) to place the 314S residue 
in a solvent-exposed region of CagA. A disease-specific 
polymorphism at this site may easily interact with other 
downstream signal molecules just under the plasma 
membrane in B-lymphocytes. Tyrosine phosphorylation 
Table 5 Difference of amino acid frequency at loci: comparison of each disease in genotypes of vacA s1m1 type
Position Amino acid 
residue
Gastric cancer (GC) 
(n = 15)
MALT (n = 10) P value Gastritis (G) (n = 18) P value
26,695 F32 GC vs MALT G vs GC G vs MALT
672I 672I I 9 1 0.033 8 0.49 0.19
V 6 8 10
Sequence gap 0 1 0
921D 921N D 0 3 0.042 8 0.0036 (P < 0.01) 0.69
N 15 6 10
Sequence gap 0 1 0
1037N 1037S S 13 6 0.042 16 0.16 0.30
N 2 0 0
G 0 3 2
Sequence gap 0 1 0
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of EPIYA/T B-TPMs were reported to be involved in the 
regulation of host cell signaling cascades and interacted 
with epithelial cells [30]. In this study, most strains pos-
sessed EPIYA, not EPIYT B-TPMs, which were in agree-
ment with the previous report that most East Asian 
strains (91.1%) possessed EPIYA B-TPMs [30].
One of the three significant VacA loci, position 672 is 
located in p55 domain. VacA p55 plays an important role 
in mediating VacA binding to host cells and the crystal 
structure of VacA p55 domain had already been reported 
using strain 60,190 [32]. The position 672 (correspond-
ing to position 636 in strain 60,190) is located in middle 
region at the 25th β-helix structure from N-terminus of 
VacA p55 (Fig. 2), exposing to outside of p55 molecule in 
the 3D-model of VacA p55 of strain 60,190. It is unclear 
whether the function of VacA can be different between 
Valine (mainly in MALT lymphoma) and Isoleucine 
(mainly in GC) in this position. However, the most diver-
gent amino acids among VacA molecule were located in 
surface-exposed residues within the p55 domain; there-
fore these residues should be involved in the optimized 
binding of VacA to different receptors or targets in host 
cells [33]. Several VacA receptors in host cells have been 
unveiled recently [34], and we hope that the binding posi-
tion of p55 domain to each receptor will be clarified in 
the future studies.
The second VacA loci obtained from comparing GC 
and MALT lymphoma sequences, position 921 was inter-
estingly, also highly significant between GC and gastritis. 
The amino acid at this position in all 15 GC strains was 
asparagine (N). Among gastritis and MALT strains, this 
site alternated between D and N (D: 8 gastritis, 3 MALT 
strains; N: 10 gastritis, 6 MALT strains). Reference Japa-
nese strain F32, which derived from a GC case, also had 
921N. These observations suggested that D to N at posi-
tion 921 at later stages of gastritis might be involved with 
the development of GC. Position 921 is located within 
the secreted alpha-peptide (SAP) region (Figs. 2, 3). SAP 
is cut and secreted from H. pylori with the mature VacA 
p88 [32, 35]. Hydrophobicity of asparagine (N) may pos-
sibly affect differently from hydrophilic aspartic acid (D) 
in this small peptide of unknown function. Detailed stud-
ies including on function of SAP are necessary to under-
stand this 921N preference in VacA of GC strains.
This study had several limitations. First, the sample 
number was small. Although we found several statisti-
cally different loci between GC and MALT lymphoma, 
the differences were marginal, and their biological impor-
tance was unclear. In this study, we focused on the two 
major virulence factors; however, H. pylori genomes 
contain more than 1500 genes. If we were to compile the 
amino acid differences across entire H. pylori genomes 
AA site in 26695 and F32 664 672 680 913 921 929 1037
FDGQITLN59662 I N N Q G T I N Y Q T L L I D S H D A G Y A R Q M I A I G G T S L N N G G N A S L Y G
.N....V.23F . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
Strain ID_disease
00-255_GC . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
00-37_GC . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
00-504_GC . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . . . . . T . . . .
02-729_GC . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
04-140_GC . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
05-134_GC . V . . . . . . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
05-423_GC . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
07-223_GC . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
10-252_GC . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
10-354_GC . V . . . . N . V . . . . A . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
10-358_GC . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
10-416_GC . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
10-447_GC . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
10-453_GC . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . . . . . . . . . .
11-9_GC . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
01-543_MALT . V . . . . N . V . . . . . . . . . . . . . . . . . . . . . . T . . . . . . A . . . S . . . T . . . .
02-767_MALT . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
04-303_MALT . V . . . . N . V . . . . . . . . . . . . . . . . . . . . . . T . . . . . . A . . . G . . . T . . . .
10-442_MALT . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
97-474_MALT . V . . . . N . V . . . . . . . . . . . . . . . . . . . . . . T . . . . . . A . . . S . . . T . . . .
99-597_MALT . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . G . . . T . . . .
14-200_MALT . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
13-330_MALT . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
09-294_MALT . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . G . . . T . . . .
10-456_MALT - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
00-466_G . V . . . . N . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . A . . . G . . . T . . . .
01-381_G . V . . . . N . V . . . . . . . . . . . . . . . . . . . . . . T . . . . . . A . . . G . . . T . . . .
01-301_G . . . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
01-383_G . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
01-617_G . V . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . S . . . T . . . .
01-540_G . V . . . . N . V . . . . . . . . . . . . . . . . . . . . . . T . . . . . . A . . . S . . . T . . . .
02-331_G . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
01-365_G . V . . . . N . . . . . . . . . . . . . . . . . . . . . . . . T . . . . . . A . . . S . . . T . . . .
02-425_G . V . . . . N . . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
01-23_G . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
01-487_G . V . . . . N . V . . . . . . . . . . . . . . N . N . . . . . T . . . . . . A . . . S . . . T . . . .
.N....V.G_2-30 V . . . . . . . . . . . . . . . . . . . . . . T . . . . . . A . . . S . . . T . . . .
03-132_G . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
01-633_G . V . . . . N . V . . . . . . . . . . . . . . . . . . . . . . T . . . . . . A . . . S . . . T . . . .
.N....V.G_8-30 . . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
00-693_G . V . . . . N . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . A . . . S . . . T . . . .
01-375_G . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .
01-643_G . V . . . . N . V . . . . . . . . . . . . . . . . N . . . . . T . . . . . . A . . . S . . . T . . . .






Fig. 2 VacA amino acid comparison between MALT lymphoma, gastric cancer, and gastritis strains. VacA amino acid comparison of strains 26,695, 
F32, and clinical isolates obtained in Oita, Japan are presented. Three significantly different loci are shown in white letters with black background. 
VacA structure was referred to [32]. GC gastric cancer, G gastritis
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between different diseases, some of the resulting loci may 
be polymorphisms important to the development of spe-
cific diseases. Further studies using isogenic mutants of 
the loci may be necessary to clarify the function of these 
amino acid differences. Second, many gastritis cases con-
tained gastric atrophy since most infected Japanese had 
gastric atrophy in some degree. Therefore, most loci 
seemed to show no difference in amino acid frequency 
between GC and MALT lymphoma sequences. Although 
NGS technology is proposed wide variety of appre-
ciation for biological problems [36], there are also some 
limitations to using currently available NGS data. In most 
cases, NGS data alone could not obtain even the full cagA 
and vacA sequences; classical Sanger methods were nec-
essary to confirm these sequences. The accuracy of NGS 
data is improving; in the near future we will use NGS to 
search for novel polymorphisms related to specific gas-
troduodenal diseases.
Despite these limitations, our methodology does offer 
a promising means of finding novel H. pylori-polymor-
phisms associated with specific diseases that involves 
NGS analysis.
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